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Using a multidisciplinary approach, we have measured various indicators of DNA damage in peripheral
lymphocytes ofhumanpopulations potentiallyatincreasedriskforcancer. Sisterchromatidexchanges(SCE)
andpolycyclicaromatichydrocarbon (PAH)-DNAadductswereevaluatedinagroupoffirefighters;chromoso-
mal aberrations and hprt mutations were evaluated in a group of cancer patients undergoing radieim-
munoglobulin therapy (RIT); SCE and acrolein-modified DNA were measured in cancer chemotherapy
patientsandinpharmacistspreparingchemotherapyprescriptions; andSCEandPAlH-DNAadductsarebeing
measured in U.S. army troops stationed in Kuwait. Our results indicate that both SCE and PAH-DNA adduct
levelswere notelevatedinfirefighters,butthatotherfactorssuchassmokingstatusandracewereriskfactors
for increased SCE and PAH-DNA adducts. RIT was found to increase background rates ofchromosome-type
aberrations and frequencies ofhprt mutations and there was a strong correlation between levels oftherapy-
induced chromosome damage sustained in vivo and in vitro sensitivity to radiation-induced chromosome
damage.Peripheralbloodlymphocytes ofcancerpatientstreatedwithcyclophosphamide showedhigherlevels
of SCE and had a higher incidence of acrolein adducts in DNA. Lymphocytes from pharmacists preparing
antineoplastic drugs were found to acquire increased in vitro sensitivity to SCE induction byphosphoramide
mustard with increased lifetime duration ofdrug handling. Aprospective, longitudinal study was performed
toidentifyenvironmental factorsthatmodulategenetic damage inbreastcancerpatients.Womenwithbenign
breastmasses andnoapparentdiseaseservedascontrols.Mutantfrequency,cloningefficiency, andchromoso-
mal aberration frequency did not differ significantly among the three groups. The results described and the
databeinggathered on troops stationed in Kuwait suggest that all the methodologies described can be useful
in screening human populations for mutagenic exposures.
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Introduction
Induction of DNA damage and the resulting adverse
sequelae such as mutations and chromosomal rearrange-
ments aretheprimarymechanismsforinductionofcancer.
Recent studies have shown how these events are involved
in activation ofdominant oncogenes and theinactivation of
tumor-suppressor genes (1). This information permits the
design of multidisciplinary approaches for monitoring
human populations for exposure to carcinogenic agents.
These approaches have used the collaborative efforts of a
numberofdisciplines includingepidemiology, occupational
medicine, cytogenetics, immunology, molecular biology,
and statistics.
This paper summarizes the results of previously pub-
lished studies on groups offirefighters, pharmacists, and
cancer patients. These groups have been exposed to a
number ofmodalities including pyrolysis and combustion
products, cytotoxic drugs, and radioimmunoglobulins.
End points examined in these populations include chro-
mosomal aberrations, sister chromatid exchanges, hprt
mutations, and DNA adducts. The utility and disadvan-
tages ofeachoftheseendpoints andpotentiallyconfound-
ing variables are discussed.
Results and Discussion
Firefighters
Firefighters are exposed to potentially carcinogenic
combustion and pyrolysis products during the course of
theirwork.A groupof43firefightersandmatchedcontrols
were examined for DNA damage that may be related to
occupational carcinogen exposures (2). Using peripheral
blood lymphocytes, we examined a) baseline sister chro-
matid exchange (SCE) frequency, b) SCE induction by in
vitro challenge with mitomycin C, and c) PAH-DNA
adduct levels. Occupational exposures were determined
from histories offirefighting activity, and the presence of
confounding factors (e.g., tobacco smoking, charcoal-
Table 1. Distribution ofvariables among firefighters and controls.
Variable Firefighters Controls
Number ofmen 43 40
Mean age, years 33.9 34.6
Tobacco users 21 15
Cigarettes/day 22.1 24.9
Charcoal-broiled food 29 13
(>3 times/month) 13 4
Alcohol consumption 26 21
(daily) 8 6
broiled food consumption, alcohol consumption) were
determined by questionnaire (Table 1). Plasma cotinine
levels weremeasured to assess recent exposure totobacco
smoke.
SCE. Mean baseline SCE frequencies were lower in 42
firefighters (8.44 SCE/cell) than in 38 controls (9.23 SCE/
cell, p = 0.02: Table 2). In addition to firefighting, the
effects ofother risk factors were evaluated. Smoking was
associatedwithincreasedbaseline SCE.Adose-response
relationship between serum cotinine level and baseline
SCE was shown (p = 0.0006), with anincrementof0.0033
SCE/cell for each nanogram of cotinine per milliliter of
serum. Race proved to be a risk factor for elevated SCE
levels, with nonwhites showing a higher mean baseline
frequency thanwhites. Two doses ofmitomycin C (MMC;
10 and 20ng/mL) wereused as achallenge to determineif
prior mutagenic exposure alters in vitro response to
mutagenic challenges. To remove the uncertain effects of
the observed baseline SCE frequency, the MMC induc-
ibility of SCE was calculated by linear regression. When




PAH-DNA Adducts. Firefighting was not associated
with significant risk for PAH-DNA adducts or benzo[a]-
pyrene diol epoxide (BPDE)-DNA antigenicity as mea-
sured byELISA (3) in DNAofnucleated peripheral blood
samples (Table3). However, smokingand alcohol consump-
tion werepositivelyassociatedwith antigenicity(p = 0.09
and p = 0.07, respectively). No association was found
between baseline frequency of SCE and the presence of
PAH-DNA adducts.
Hepatoma Patients Treated with
Radioimmunoglobulin Therapy
Lymphocytes from patients undergoing radioim-
munoglobulin therapy (RIT) were examined for chromo-
someaberrationsexpressedimmediately uponexplantand
for chromosome aberrations induced by subsequent chal-
lengewith y radiation afterPHA-stimulated proliferation.
Inaddition, hprt mutantfrequencies were assessed inthis
same population. Primary hepatoma patients who are
candidatesforRIT arecyclicallyinjected atapproximately
8-week intervals with 30 mCi of 131I-labeled antiferritin.
Each cycle results in a whole body radiation dose of
approximately 0.3 Gy.
Table 2. Unadjusted baseline sister chromatid exchange frequency amongfirefighters and controls by two risk factors.
Firefighters Controls
Smoker Nonsmoker Total Smoker Nonsmoker Total
n Mean + SD n Mean ± SD n Mean + SD n Mean ± SD n Mean + SD n Mean ± SD
Total 16 9.11 ± 0.93 26 8.02 ± 1.25 42 8.44 ± 1.25 14 9.61 ± 1.89 24 9.01 ± 1.42 38 9.23 ± 1.61
Broiled food (-) 6 9.42 + 1.42 7 8.53 ±1.83 13 8.94 ± 1.65 13 9.71 ± 1.93 12 8.47 ± 1.10 25 9.11 ± 1.68
Broiled food (+) 10 8.93 ± 0.48 19 7.84 ± 0.96 29 8.21 ± 0.97 1 8.39 12 9.54 ± 1.55 13 9.46 ± 1.52
Nonwhite 4 9.62 ± 0.23 2 7.91 ± 0.40 6 9.05 ± 0.91 6 9.89 ± 1.94 3 10.3 ± 0.46 9 10.0 ± 1.56
White 12 8.94 ± 1.02 24 8.03 ± 1.30 36 8.34 + 1.28 8 9.40 + 1.95 21 8.83 ± 1.95 29 8.89 ± 1.57
122GENETIC MONITORING OF HUMAN POPULATIONS AT RISK FOR CANCER
Table 3. Polyaromatic hydrocarbon-DNA adduct-positive rates and associated odds ratios among firefighters and controls by risk factors.
Firefighters Controls Totala
n Positiveb % n Positiveb (%) OR 95% CI OR CI
Total 43 15 (35) 38 13 (34) 1.03 0.41-2.58
Smoker 17 7 (41) 15 8 (53) 0.61 0.15-2.49 2.44 0.96-6.26
Nonsmoker 26 8 (31) 23 5 (22) 1.60 0.44-5.84
Nonwhite 6 0 (0) 9 6 (67) 0.04 0.002-0.97 1.33 0.42-4.22
White 37 15 (41) 29 7 (24) 2.14 0.73-6.27
Alcohol
Daily 8 6 (75) 6 2 (33) 6.00 0.58-62.1 3.13 0.96-10.2
Others 35 9 (26) 32 11 (34) 0.66 0.23-1.89
Broiled food (+) 29 7 (24) 12 2 (17) 1.59 0.28-9.07 0.31 0.12-0.82
Times >3/month 13 6 (46) 4 4 (25) 2.57 0.21-31.7 0.77 0.25-2.44
Times <3/month 16 1 (6) 8 1 (13) 0.47 0.03-8.60 0.10 0.02-0.49
Broiled food (-) 14 8 (57) 26 11 (42) 1.82 0.49-6.76
Abbreviations: OR, odds ratio; CI, confidence interval.
aCompared to other dichotomy, e.g., smokers versus nonsmokers, nonwhite versus white.
bNumber with measurable (positive) adduct levels.
Chromosomal Aberrations. Lymphocytes from indi-
vidual patients undergoing radiolabeled immunoglobulin
therapy were examined both for chromosome aberrations
expressed immediately upon explant, or for chromosome
aberrations induced by a subsequent challenge of -y-rays
after phytohemagglutin-stimulated proliferation (4).
Despiteinterpatientvariation,thereisastrongcorrelation
betweenlevels ofchromosome aberrations observed in the
initial mitosis aftermitogenic stimulation and levels induced
by a challenge dose ofradiation in replicate cultures after
several cellcyclesofgrowth (Fig. 1).Thesedataindicatethat
even after proliferation, human lymphocytes retain a mem-
ory of in vivo exposure to ionizing radiation that can be
observed by challenge with a clastogenic agent.
Hprt Gene Mutations. Gene mutations induced in vivo
can be measured at the hprt locus in human T-lympho-
cytes. Twenty-eight patients receiving 131I and/or 90Y-
labeled antiferritin were studied for mutant frequencies
and compared to acontrolpopulation (5,6). Majorobserva-
tionsresultingfromthesestudieswerea)mutantfrequen-
cies for patients were increased by an order ofmagnitude
compared to nontreated controls (68.0 x 10-6 versus 6.8
X 10-6); b) there was a good correlation between mutant
frequency and the amount of radioactivity given in the
first treatment; however, there was a poor correlation
between mutant frequency and the total amount of
injected isotope over several cycles of treatment; c)
molecular analyses ofmutant clones indicated that radia-
tioninduces ahigherfrequencyofgross structural altera-
tions (detectable by Southern blotting) than occur in
spontaneous mutations; and d) T-cell receptor analysis
showed that 84% ofmutants arose independently, approx-
imately the same as in seen in control populations.
Cancer Patients Treated with
Cyclophosphamide
Cyclophosphamide is a chemotherapeutic alkylating
drug commonly used in the treatment of breast cancer,
hematopoietic and lymphatic cancers, as well as other
malignancies. Cyclophosphamide is a known human car-
cinogen associated with increased risk for secondary,
treatment-associated cancers, most commonly myelogen-
ous leukemias. Major metabolic products associated with
cytotoxicity and carcinogenicity are phosphoramide mus-
tard and acrolein. We studied cancerpatients treatedwith
cyclophosphamide and pharmacists involved in preparing
anticancer drugs (7,8).
Acrolein Adducts. Blood specimens were obtained from
27cancerpatientswhohadprimarilybreastandhematologi-
cal malignancies. Twelve patients had been therapeutically
treated with a regime that included cyclophosphamide
while 15 patients were newly diagnosed, untreated, and
served ascontrols.Acroleinadductsweremeasured either
by ELISA or immunodot blot (IDB). The ELISA assay
gave positive results in 4 of12 treated patients and in 0 of
15 nontreated patients. The IDB assay fared slightly bet-
teridentifying 6 of12 treated patients as positive and 0 of
15 untreated controls (Table 4). No clear trends emerged
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FIGURE 1. Chromosomal radiosensitivity of cells from radioimmuno-
globulin therapy patients displayed as a function oflevels ofchromosome
damage sustained in vivo. Symmetrical chromosome-type aberrations
were scored infirst-division metaphases. Parallel cultures from the same
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¶Ible 4. Acrolein-DNA detection.
Number of Number of
CP-treated patients untreated patients
Detection method (positive/tested) (positive/tested)
ELISA 4/12 0/15
IDB 6/12 0/16
Abbreviations: ELISA, enzyme-linked immunosorbent assay; IDB,
immunodotblot; CP, cyclophosphamide.
afunction oflifetime cyclophosphamide dose, recenttreat-
ment, time since last treatment, treatment regime, or
smoking history.
SCE. Blood specimens were obtained from 39 cancer
patients; 19 treated with cyclophosphamide and 20 un-
treated controls. Therapeutically treated patients showed
statisticallyhigherbaseline SCE frequenciesthatcontrols
(p < 0.016) andreturned tobaselinein4-6weeks afterthe
last treatment dose. Cultured cells from patients treated
with cyclophosphamide showed similar in vitro responses
to challenge doses ofphosphoramide mustard as did cells
from control patients.
Pharmacists Handling Anticancer Drugs
SCE. Bloodspecimenswereobtainedfrom34pharmacy
workers who had varying duration of anticancer drug
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ering past medical history, family history, current smok-
ing, alcohol, diet, medication, and lifetime occupational
history. The mean baseline SCE for the population was
5.19 ± 0.17 and was not correlated with duration ofdrug
handling. However, astrongcorrelationwasdemonstrated
between inducible SCE values and lifetime duration of
drug handling for low-dose phosphoramide challenge (0.1
mg/mL, r=0.63p < 0.0001) and forhigh-dosephosphora-
mide challenge (0.25 mg/mL, r = 0.59p < 0.0001, Fig. 2).
Women with Benign and Malignant Breast
Masses
A prospective, longitudinal study was performed to
identity environmental factors that modulate genetic
damageinbreastcancerpatients(10).Atotalof107women
(49withbreast cancer, 52with benignbreastmasses, and
6 normal women) were enrolled.
HprtAnalysis, ChromosomalAberrations, andSCE.
Mutant frequency at the hprt locus and cloning efficiency
of peripheral blood lymphocytes did not differ signifil-
cantly among the three groups. Mutant frequency
increasedwith age,historyofcigarette smoking, andtotal
number ofyears smoking. Chromosomal aberrations fre-
quencies were similar in lymphocytes of 28 women with
benign breast disease (5.3 ± 2.7 aberrations/100 cells)
compared to 11 breast cancer patients (5.2 ± 2.1 aberra-
9-
9
Total Exposure Hours (Log)
FIGURE 2. Scatterplot and regression ofmean sister chromatid exchange (SCE) challenge minus baseline with lifetime antineoplastic drug exposure.
(*) High concentration ofphosphoramide mustard challenge (0.25 ,ug/mL) minus baseline SCE; (*) low-dose phosphoramide mustard challenge (0.1
,ug/mL) minus baseline.
# High Dose: r - .67 (p<.000Oi) *
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tions/100 cells). The mean SCE incidence in lymphocytes
from23womenwithbenigndiseasewas9.3 ± 1.6,whereas
the rate in cells from 8 cancerpatients was 7.5 ± 1.6 (p =
0.01). However, 14 of the former group were smokers,
whereas only one of the cancer patients smoked. There
wasnocorrelationbetweenthehprtmutantfrequencyand
either aberrations or SCE.
American froops Stationed in Kuwait
We are currently studying a cohort of 60 American
troops deployed to Kuwait after Desert Storm. The U.S.
government is concerned about potential health hazards
associated with pollutants generated by oil-well fires.
Blood samples were drawnbefore deployment, at onetime
pointafter8weeksinKuwait,andatanother4weeksafter
returningto Germany. SCE andlevels ofPAHadducts are
currently being quantified in this longitudinal study.
Conclusions
We haveused batteries ofcytogenetic, biochemical, and
molecular techniques to monitor diverse human popula-
tions who may be at increased risk for cancer because of
exposuresrelatedtooccupation,lifestyle, ormedicaltreat-
ment. Each endpointhasbenefits and disadvantages. For
example, induction of SCE is a sensitive end point for
certain chemical exposures, especially for exposure to
cigarette smoke. However, SCE frequencies respond only
marginally to ionizing radiation. In addition, the signifi-
cance of SCE induction is still not clear. Mutation at the
hprt locus has proved to be a sensitive indicator of expo-
sure to a variety of agents. On theoretical grounds, how-
ever, it is limited to the detection agents that induce point
mutations; agents inducing primarily chromosome dele-
tions would not be detected. Additionally, hprt mutations
do not appear to occur in stem cells because mutant
frequencies return to normal levels in 2-3 months after
cessation ofexposures. Use ofantibodies against specific
DNA adducts has the advantage of a high level ofspecif-
icity for particular types of damages. Clearly, such an
approach would not be useful for general screening. Also,
because DNAadducts are repairable, they are considered
asprecursors togenetic events. Detection ofDNAadducts
using antibodies also appears more specific than sensitive
(more subject to false negatives than false positives).
Chromosomal aberration analysis has been the most
widelyusedofanyoftheendpoints.Aberrationshavebeen
foundtopersistintheperipheralbloodforformanyyears,
as has been noted for the survivors of Hiroshima and
Nagasaki. One must always remember, however, that the
cytogenetics eventsthataregenerallyscoredarecytotoxic
to the cells that display them and therefore are of no
genetic consequence.
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